WuXi Biologics (Cayman) Gestion

Gestion contrôle des critères 2/4

Le PDG WuXi Biologics (Cayman) est Chris Chen, nommé en Jan2016, a un mandat de 8.83 ans. La rémunération annuelle totale est CN¥ 96.91M, composée du salaire de 4.1% et des bonus 95.9%, y compris les actions et options de la société. détient directement 0.35% des actions de la société, d'une valeur de € 25.74M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.6 ans et 7.2 ans.

Informations clés

Chris Chen

Directeur général

CN¥96.9m

Rémunération totale

Pourcentage du salaire du PDG	4.1%
Durée du mandat du directeur général	8.8yrs
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	2.6yrs
Durée moyenne du mandat des membres du conseil d'administration	7.2yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Chris Chen a-t-elle évolué par rapport aux bénéfices de WuXi Biologics (Cayman)?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Rémunération vs marché: La rémunération totale de Chris ($USD 13.38M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 3.58M ).

Rémunération et revenus: La rémunération de Chris a augmenté de plus de 20 % tandis que les bénéfices de l'entreprise ont chuté de plus de 20 % au cours de l'année écoulée.

PDG

Chris Chen (51 yo)

8.8yrs

Titularisation

CN¥96,911,000

Compensation

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ge Li	Founder & Chairman	10.8yrs	pas de données	pas de données
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% € 25.7m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% € 984.4k
Ming Tu	CFO & Executive VP	3yrs	pas de données	pas de données
Lihua Yu	COO & Senior VP	less than a year	pas de données	pas de données
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	pas de données	pas de données
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	pas de données	pas de données
Lina Fan	Senior VP & Head of Investor Relations	less than a year	pas de données	pas de données
He Wang	Chief Compliance Officer	2.2yrs	pas de données	pas de données
Li Xiong	VP & Head of Global Human Resources	no data	pas de données	pas de données
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	pas de données	pas de données
Keqiang Shen	Chief Digital Officer	4.8yrs	pas de données	pas de données

2.6yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1FW2 est considérée comme expérimentée (ancienneté moyenne 2.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ge Li	Founder & Chairman	10.8yrs	pas de données	pas de données
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% € 25.7m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% € 984.4k
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% € 45.9k
James Larrick	Member of Scientific Advisory Board	6.8yrs	pas de données	pas de données
David D. Ho	Member of Scientific Advisory Board	6.8yrs	pas de données	pas de données
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	pas de données	pas de données
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	pas de données	pas de données
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% € 38.6k
Yanling Cao	Non-Executive Director	8.5yrs	pas de données	pas de données
Yibing Wu	Non-Executive Director	8.5yrs	pas de données	pas de données
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% € 360.9k

7.2yrs

Durée moyenne de l'emploi

59.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1FW2 sont considérés comme expérimentés (ancienneté moyenne 7.2 ans).

WuXi Biologics (Cayman) Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

CEO & Executive Director recently sold €784k worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Board Member recently sold €2.9m worth of stock

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 22%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 17%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold €784k worth of stock

Investor sentiment deteriorates as stock falls 20%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 16%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 32%

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Board Member recently sold €2.9m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

Investor sentiment deteriorates as stock falls 22%

Now 23% undervalued after recent price drop

CEO & Executive Director recently sold €1.5m worth of stock

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold €740k worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Now 21% undervalued

CEO & Executive Director recently sold €2.1m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction